AMY BOGGS: Open Payments
NPI 1629370291 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,146 in 181 payments from 17 companies in 2025. Trend: 2023 $3,805 · 2024 $2,958 · 2025 $3,146
Food & beverage: $3,146
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 36 | $536 |
| Neurocrine BioSciences, Inc. | 18 | $353 |
| Otsuka America Pharmaceutical, Inc. | 20 | $343 |
| ABBVIE INC. | 31 | $341 |
| Janssen Pharmaceuticals, Inc | 17 | $264 |
| Alkermes, Inc. | 13 | $237 |
| Teva Pharmaceuticals USA, Inc. | 8 | $178 |
| Supernus Pharmaceuticals, Inc. | 4 | $175 |
| E.R. Squibb & Sons, L.L.C. | 9 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
Products named: CAPLYTA, INGREZZA, VRAYLAR, REXULTI, SPRAVATO, Qelbree, COBENFY, TRINTELLIX.
Industry payments across OK — which companies pay providers there.
